BPH Energy

BPH Energy Limited is a diversified company based in North Perth, Australia, engaged in biomedical research and oil and gas exploration. The company focuses on developing innovative biomedical technologies, including the Brain Anaesthesia Response (BAR) Monitor, which assesses brain electrical activity in response to surgical drugs, and the HLS5 Tumour Suppress Gene, a genetic marker aimed at facilitating early cancer detection. BPH Energy also holds significant interests in oil and gas assets, including a 100% ownership of RL1 in the Bonaparte basin and an 85% interest in an offshore exploration permit in the Sydney basin. Additionally, the company is involved in the medicinal cannabis sector. BPH Energy was previously known as BioPharmica Limited and has been operational since 2001.